相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT
Annalisa Ruggeri et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Decitabine Inhibits Gamma Delta T Cell Cytotoxicity by Promoting KIR2DL2/3 Expression
Chao Niu et al.
FRONTIERS IN IMMUNOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
G. Bug et al.
LEUKEMIA (2017)
Decitabine inhibits T cell proliferation via a novel TET2-dependent mechanism and exerts potent protective effect in mouse auto- and allo-immunity models
Xue Wang et al.
ONCOTARGET (2017)
Hematopoietic stem cell transplantation for patients with AML in first complete remission
Jan J. Cornelissen et al.
BLOOD (2016)
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
Charles Craddock et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review
Armin Rashidi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
Madan H. Jagasia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Iskra Pusic et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome
Seunghoon Han et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia
Jonathan How et al.
LEUKEMIA & LYMPHOMA (2015)
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
Christopher G. Kanakry et al.
BLOOD (2014)
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome
Mark Kirschbaum et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Impact of 5-aza-2-deoxycytidine and epigallocatechin-3-gallate for induction of human regulatory T cells
Jan Kehrmann et al.
IMMUNOLOGY (2014)
Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning
Christopher G. Kanakry et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning
Anna Maria Raiola et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation
Stefan O. Ciurea et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Early allo-SCT for AML with a complex aberrant karyotype-results from a prospective pilot study
C. Schmid et al.
BONE MARROW TRANSPLANTATION (2012)
Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia
M. Terwijn et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2012)
Comparative Analysis of the Value of Allogeneic Hematopoietic Stem-Cell Transplantation in Acute Myeloid Leukemia With Monosomal Karyotype Versus Other Cytogenetic Risk Categories
Jan J. Cornelissen et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
U. Platzbecker et al.
LEUKEMIA (2012)
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
Leo Luznik et al.
BLOOD (2010)
Maintenance Therapy With Low-Dose Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for Recurrent Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Marcos de Lima et al.
CANCER (2010)
High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation
Leo Luznik et al.
IMMUNOLOGIC RESEARCH (2010)
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials
John Koreth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Cyclophosphamide and cancer: golden anniversary
Ashkan Emadi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Leo Luznik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Decitabine and its role in the treatment of hematopoietic malignancies
Elizabeth R. Plimack et al.
LEUKEMIA & LYMPHOMA (2007)
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
Guillermo Garcia-Manero et al.
BLOOD (2006)
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2006)
Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors
T Kikuchi et al.
ONCOGENE (2002)
分享论文
